Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

NCT02057835 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Placebo to BI 691751
DRUG: BI 691751 high dose
DRUG: BI 691751 middle dose
DRUG: Placebo to BI 691751
DRUG: BI 691751 low dose 1
DRUG: Placebo to BI 691751
DRUG: Placebo to BI 691751
DRUG: BI 691751 low dose 2

Sponsor

Boehringer Ingelheim